Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants

被引:323
作者
Stark, AR
Carlo, WA
Tyson, JE
Papile, L
Wright, LL
Shankaran, S
Donovan, EF
Oh, W
Bauer, CR
Saha, S
Poole, WK
Stoll, BJ
机构
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Univ Alabama, Birmingham, AL USA
[3] Univ Texas, Houston, TX USA
[4] Univ New Mexico, Albuquerque, NM 87131 USA
[5] NICHHD, Bethesda, MD 20892 USA
[6] Wayne State Univ, Detroit, MI USA
[7] Univ Cincinnati, Cincinnati, OH USA
[8] Brown Univ, Women & Infants Hosp, Providence, RI USA
[9] Univ Miami, Miami, FL 33152 USA
[10] Res Triangle Inst, Res Triangle Pk, NC 27709 USA
[11] Emory Univ, Atlanta, GA 30322 USA
[12] Case Western Reserve Univ, Cleveland, OH 44106 USA
[13] Yale Univ, New Haven, CT USA
[14] Univ Tennessee, Memphis, TN USA
[15] Stanford Univ, Stanford, CA 94305 USA
关键词
D O I
10.1056/NEJM200101113440203
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Early administration of high doses of dexamethasone may reduce the risk of chronic lung disease in premature infants but can cause complications. Whether moderate doses would be as effective but safer is not known. Methods: We randomly assigned 220 infants with a birth weight of 501 to 1000 g who were treated with mechanical ventilation within 12 hours after birth to receive dexamethasone or placebo with either routine ventilatory support or permissive hypercapnia. The dexamethasone was administered within 24 hours after birth at a dose of 0.15 mg per kilogram of body weight per day for three days, followed by a tapering of the dose over a period of seven days. The primary outcome was death or chronic lung disease at 36 weeks' postmenstrual age. Results: The relative risk of death or chronic lung disease in the dexamethasone-treated infants, as compared with those who received placebo, was 0.9 (95 percent confidence interval, 0.8 to 1.1). Since the effect of dexamethasone treatment did not vary according to the ventilatory approach, the two dexamethasone groups and the two placebo groups were combined. The infants in the dexamethasone group were less likely than those in the placebo group to be receiving oxygen supplementation 28 days after birth (P=0.004) or open-label dexamethasone (P=0.01), were more likely to have hypertension (P<0.001), and were more likely to be receiving insulin treatment for hyperglycemia (P=0.02). During the first 14 days, spontaneous gastrointestinal perforation occurred in a larger proportion of infants in the dexamethasone group (13 percent, vs. 4 percent in the placebo group; P=0.02). The dexamethasone-treated infants had a lower weight (P=0.02) and a smaller head circumference (P=0.04) at 36 weeks' postmenstrual age. Conclusions: In preterm infants, early administration of dexamethasone at a moderate dose has no effect on death or chronic lung disease and is associated with gastrointestinal perforation and decreased growth. (N Engl J Med 2001;344:95-101.) Copyright (C) 2001 Massachusetts Medical Society.
引用
收藏
页码:95 / 101
页数:7
相关论文
共 33 条
  • [1] SPONTANEOUS FOCAL GASTROINTESTINAL PERFORATION IN VERY LOW BIRTH-WEIGHT INFANTS
    ASCHNER, JL
    DELUGA, KS
    METLAY, LA
    EMMENS, RW
    HENDRICKSMUNOZ, KD
    [J]. JOURNAL OF PEDIATRICS, 1988, 113 (02) : 364 - 367
  • [2] BUCHHEIT JQ, 1994, PEDIATRICS, V93, P32
  • [3] Carlo WA, 1999, PEDIATRICS, V104, P738
  • [4] Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia
    Cole, CH
    Colton, T
    Shah, BL
    Abbasi, S
    MacKinnon, BL
    Demissie, S
    Frantz, ID
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (13) : 1005 - 1010
  • [5] Longitudinal growth of hospitalized very low birth weight infants
    Ehrenkranz, RA
    Younes, N
    Lemons, JA
    Fanarof, AA
    Donovan, EF
    Wright, LL
    Katsikiotis, V
    Tyson, JE
    Oh, W
    Shankaran, S
    Bauer, CR
    Korones, SB
    Stoll, BJ
    Stevenson, DK
    Papile, LA
    [J]. PEDIATRICS, 1999, 104 (02) : 280 - 289
  • [6] A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: A randomized trial
    Garland, JS
    Alex, CP
    Pauly, TH
    Whitehead, VL
    Brand, J
    Winston, JF
    Samuels, DP
    McAuliffe, TL
    [J]. PEDIATRICS, 1999, 104 (01) : 91 - 99
  • [7] Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids
    GoppeltStruebe, M
    [J]. BIOCHEMICAL PHARMACOLOGY, 1997, 53 (10) : 1389 - 1395
  • [8] EFFECTS OF DEXAMETHASONE ON CHEMOTACTIC ACTIVITY AND INFLAMMATORY MEDIATORS IN TRACHEOBRONCHIAL ASPIRATES OF PRETERM INFANTS AT RISK FOR CHRONIC LUNG-DISEASE
    GRONECK, P
    REUSS, D
    GOTZESPEER, B
    SPEER, CP
    [J]. JOURNAL OF PEDIATRICS, 1993, 122 (06) : 938 - 944
  • [9] Clinical trials of postnatal corticosteroids: Inhaled and systemic
    Halliday, HL
    [J]. BIOLOGY OF THE NEONATE, 1999, 76 : 29 - 40
  • [10] HARDMAN JG, 1996, GOODMAN GILMANS PHAR, P622